60
Participants
Start Date
May 31, 2006
Primary Completion Date
September 30, 2007
Study Completion Date
December 31, 2007
YSPSL
YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
placebo
0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
YSPSL
YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
Westchester Medical Center, New York Medical College, Hawthorne
Shands Hospital at University of Florida, Gainesville
Lifelink Foundation, Tampa
Methodist Healthcare University Hospital, Memphis
University of Cincinnati, Department of Internal Medicine, Cincinnati
Henry Ford Hospital Transplant Institute, Detroit
Rush University Medical Center, Chicago
Tulane University Hospital & Clinic, New Orleans
Baylor University Medical Center Transplantation Services, Dallas
The Methodist Hospital, Houston
University of Texas, Organ Transplantation, Houston
University of Colorado Health Sciences Center, Denver
Dumont-UCLA Transplant Center, Los Angeles
California Pacific Medical Center Department of Transplantation, San Francisco
Saint Barnabas Medical Center, Livingston
Y's Therapeutics, Inc.
INDUSTRY